Fever is one of the common symptom in medical evaluation in infants and children accounting for about 65% ambulatory pediatric visits. At a temperature higher than 38.3 °C [101Fahrenheit (F), antipyretic medication is indicated.
Biologic DMARDs (bDMARDs) are first-line treatment agents for RA patients not responding to or intolerant to csDMARDs. The currently approved bDMARDs include anti-tumor necrosis factor-α agents (aTNFs), Anti-interleukin 6 receptor (IL-6R) therapy, Anti-CD20 B cell targeted therapy and T cell co-stimulation inhibition.
Tumor necrosis factor inhibitors (TNFi or anti-TNFs) have significantly contributed in improving the clinical outcomes of rheumatoid arthritis (RA), however, safety has always been a concern. Various severe infectious event (SIE) have been reported in patients using biologics.
Transdermal delivery of betamethasone valerate shows a considerable safety and efficacy in arthritis and osteoarthritis patients.
Arthritis is marked by joint pain and inflammation. The most common form of arthritis is osteoarthritis (OA) which can be described as a degenerative mesenchymal disease, affecting approximately 10% of the world’s population over 60 years.
Serum procalcitonin (PCT) levels found to be significantly lower in patients with the acute gouty attack than in patients with bacterial infection.
The acute gouty attack is an inflammatory response in which monosodium urate crystals get deposited in joints. It is characterized by redness, tenderness, swelling, and heat over inflamed joints, and systemic fever.
- 1 of 23